semaglutide approved for obesity 50 mg of oral #semaglutide daily was associated with body weight reduction and improved cardiometabolic risk factors in East Asian adults with overweight or #obesity, with or without type 2 #diabetes. https://ja.ma/41sPiYj Wegovy® – A New Treatment

doi:10.1371/journal.pmed.1002101 50

At Rejuve, we dont just give injections we create a wellness plan that fits your specific body chemistry and energy goals

The Aib substitution prevents enzymatic destruction

However, because the control beverage elicited similar lipid-lowering effects in hypercholesterolemic participants, and due to the short study duration and small sample size, further research is needed to clarify yerba mates long-term efficacy, optimal dosing, and potential role in populations with chronic conditions such as type 2 diabetes, obesity, or advanced cardiovascular disease

Two Phase 2 trials were conducted concurrently: one in adults with obesity without diabetes, published in the New England Journal of Medicine in June 2023, and one in adults with type 2 diabetes, published simultaneously in The Lancet

Coverage depends on your specific plan, but many major insurers now regard semaglutide as necessary for managing weight